ARQT vs PRGO

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcutis Biotherapeutics, Inc.

(ARQT) delivered a total return of -25. 9%, compared to -58. 6% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: ARQT returned +10. 9% versus PRGO's -76. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.

18β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 25% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcutis Biotherapeutics, Inc.

(ARQT) is the more profitable company, earning -4. 3% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

8x forward P/E versus 90. 8x for Arcutis Biotherapeutics, Inc. — 85. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 63. 1% to $20. 00.

In this comparison, PRGO (9.

4% yield) pays a dividend. ARQT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 9. 4% yield). Both have compounded well over 10 years (PRGO: -76. 8%, ARQT: +10. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARQT is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while ARQT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.